title: Targeting immunosuppression by Tregs with monoclonal antibodies against GARP.
abstract: Reducing Treg function in cancer patients should augment antitumor immune responses. We recently uncovered a mechanism of immunosuppression by human Tregs that implies transmembrane protein GARP and production of active TGF-ß1. We obtained monoclonal antibodies that block this process and could thus serve as a novel approach for cancer immunotherapy.
authors.affiliation: de Duve Institute, Université catholique de Louvain , Brussels, Belgium.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Liénart
authors.affiliation: de Duve Institute, Université catholique de Louvain , Brussels, Belgium.
authors.forename: Julie
authors.initials: J
authors.lastname: Stockis
authors.affiliation: de Duve Institute, Université catholique de Louvain , Brussels, Belgium.
authors.forename: Olivier
authors.initials: O
authors.lastname: Dedobbeleer
authors.affiliation: de Duve Institute, Université catholique de Louvain , Brussels, Belgium.
authors.forename: Sophie
authors.initials: S
authors.lastname: Lucas
keywords: Cancer immunotherapy; TGF-ß1; Tregs; immunosuppression; monoclonal antibodies